23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Fulcrum Therapeutics, Inc. › 2025-2026

Fulcrum Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Fulcrum Therapeutics, Inc.’s Form 8-K, filed June 25, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 169Asset managers, any item
  • 951Fund votes
  • June 24, 2026Meeting date

Results at a glance

Meeting of June 24, 2026: 5 items on Fulcrum Therapeutics, Inc.’s Form 8-K, filed June 25, 2026: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 1 director (19.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2024-2025 2025-2026

Activist investors: Tang Capital (13F, 9.3%, as of September 30, 2026) · Nantahala Capital (13F, 8.6%, as of September 30, 2026)

Explore Fulcrum Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Fulcrum Therapeutics, Inc.

These tallies are Fulcrum Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 25, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Fulcrum Therapeutics, Inc. — official shareholder meeting results, meeting held June 24, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sonja Banks 43,187,717---- 10,601,3855,062,117 80%Passed (calculated)—
Elect Director: Alan Ezekowitz 52,317,282---- 1,471,8205,062,117 97%Passed (calculated)—
Elect Director: Colin Hill 52,363,595---- 1,425,5075,062,117 97%Passed (calculated)—
Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers. 50,735,6173,026,39727,088 --5,062,117 94%Approved—
Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. 58,793,64536,17821,396 --0 99.9%Approved—

Source: Fulcrum Therapeutics, Inc., Form 8-K, filed with the SEC on June 25, 2026 — read the filing on EDGAR.

How asset managers voted at the Fulcrum Therapeutics, Inc. 2025-2026 meeting

169 asset managers disclosed a vote on at least one Fulcrum Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Alan Ezekowitz

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 52,317,282WITHHELD: 1,471,820
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Alan Ezekowitz

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Alan Ezekowitz”): 52,317,282 for, 1,471,820 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 9,169,393 for, 329,047 withheld, 3 abstained.

FOR
FOR: 9,169,393ABSTAIN: 3WITHHOLD: 329,047
Largest asset managers voting on “Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,243,1990 34,611For
BlackRock2,827,0140 00For
Fidelity1,253,3260 00For
Charles Schwab426,9630 00For
State Street343,7830 0106For
Dimensional00 0252,690Withhold
American Century156,2420 00For
TIAA129,6180 00For
Simplify Exchange Traded Funds116,8340 00For
Equitable94,5680 018,660Mixed
QUANTITATIVE MASTER SERIES LLC85,7810 00For
Goldman Sachs75,1940 00For
Lincoln Financial52,5480 010,042Mixed
Northern Trust43,8960 00For
Russell Investments33,6730 00For
AIG/SunAmerica29,4620 00For
Global X25,9200 00For
Bridge Builder Trust25,4810 00For
ProShares25,4560 00For
MASTER INVESTMENT PORTFOLIO24,0780 00For
Pacific Life22,5500 00For
CLEARWATER INVESTMENT TRUST20,3610 00For
Brighthouse19,2480 00For
John Hancock14,6420 00For
Jackson National00 014,631Withhold

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Colin Hill

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 52,363,595WITHHELD: 1,425,507
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Colin Hill

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Colin Hill”): 52,363,595 for, 1,425,507 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 9,174,462 for, 323,977 withheld, 3 abstained.

FOR
FOR: 9,174,462ABSTAIN: 3WITHHOLD: 323,977
Largest asset managers voting on “Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,247,8090 30For
BlackRock2,827,0140 00For
Fidelity1,253,3260 00For
Charles Schwab426,9630 00For
State Street343,8890 00For
Dimensional00 0252,690Withhold
American Century156,2420 00For
TIAA129,6180 00For
Simplify Exchange Traded Funds116,8340 00For
Equitable94,5680 018,660Mixed
QUANTITATIVE MASTER SERIES LLC85,7810 00For
Goldman Sachs75,1940 00For
Lincoln Financial52,5480 010,042Mixed
Northern Trust43,8960 00For
Russell Investments33,6730 00For
AIG/SunAmerica29,4620 00For
Global X25,9200 00For
Bridge Builder Trust25,4810 00For
ProShares25,4560 00For
MASTER INVESTMENT PORTFOLIO24,0780 00For
Pacific Life22,5500 00For
CLEARWATER INVESTMENT TRUST20,3610 00For
Brighthouse19,2480 00For
John Hancock14,6420 00For
Jackson National00 014,631Withhold

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Elect Director: Sonja Banks

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 43,187,717WITHHELD: 10,601,385
Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Sonja Banks

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Sonja Banks”): 43,187,717 for, 10,601,385 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 8,728,837 for, 769,589 withheld, 17 abstained.

FOR
FOR: 8,728,837ABSTAIN: 17WITHHOLD: 769,589
Largest asset managers voting on “Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,209,4930 1738,302For
BlackRock2,827,0140 00For
Fidelity1,236,0320 017,294For
Charles Schwab426,9630 00For
State Street343,6220 0267For
Dimensional00 0252,690Withhold
American Century00 0156,242Withhold
TIAA129,6180 00For
Simplify Exchange Traded Funds116,8340 00For
Equitable94,5680 018,660Mixed
QUANTITATIVE MASTER SERIES LLC85,7810 00For
Goldman Sachs75,1940 00For
Lincoln Financial27,9000 034,690Mixed
Northern Trust00 043,896Withhold
Russell Investments33,6730 00For
AIG/SunAmerica00 029,462Withhold
Global X25,9200 00For
Bridge Builder Trust25,4810 00For
ProShares00 025,456Withhold
MASTER INVESTMENT PORTFOLIO24,0780 00For
Pacific Life22,5500 00For
CLEARWATER INVESTMENT TRUST00 020,361Withhold
Brighthouse00 019,248Withhold
John Hancock00 014,642Withhold
Jackson National00 014,631Withhold

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 50,735,617AGAINST: 3,026,397

Prior year: 99.8% for (June 26, 2025 meeting) ▼ 5.4 pts

Details: description as filed, official tally, votes by 167 asset managers

Description as filed by funds: A non-binding advisory vote to approve the compensation of our named executive officers;

Fulcrum Therapeutics, Inc.’s own tally for this item (“Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.”): 50,735,617 for, 3,026,397 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “b) Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Fulcrum Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, no shares for or against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 51 asset managers voting on “A non-binding advisory vote to approve the compensation of our named executive officers;” at Fulcrum Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,247,8101 00For
BlackRock2,827,0140 00For
Fidelity1,253,3260 00For
Charles Schwab426,9630 00For
State Street343,82465 00For
Dimensional252,6900 00For
American Century0156,242 00Against
TIAA129,6180 00For
Simplify Exchange Traded Funds116,8340 00For
Equitable113,2280 00For
QUANTITATIVE MASTER SERIES LLC85,7810 00For
Goldman Sachs75,1940 00For
Lincoln Financial62,5900 00For
Northern Trust43,8960 00For
Russell Investments33,6730 00For
AIG/SunAmerica29,4620 00For
Global X25,9200 00For
Bridge Builder Trust25,4810 00For
ProShares25,4560 00For
MASTER INVESTMENT PORTFOLIO24,0780 00For
Pacific Life22,5500 00For
CLEARWATER INVESTMENT TRUST20,3610 00For
Brighthouse19,2480 00For
John Hancock14,6420 00For
Jackson National14,6310 00For

Fund voting reports, all 51 managers: 9,327,803 for, 156,309 against, 14,329 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 132 asset managers voting on “A non-binding advisory vote to approve the compensation of our named executive officers;” at Fulcrum Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
MONTANOVA CAPITAL, LLC6,463,8180 00For
RA CAPITAL MANAGEMENT, L.P.6,053,9600 00For
Nantahala Capital Management, LLC2,430,1530 00For
Siren, L.L.C.2,400,0000 00For
BlackRock2,237,15622,647 00For
Aberdeen02,211,953 00Against
State Street1,371,8554,039 00For
GEODE CAPITAL MANAGEMENT, LLC1,367,7920 00For
BRAIDWELL LP1,002,7180 00For
Point72996,7630 00For
Citadel778,6020 00For
ORBIMED ADVISORS LLC728,6200 00For
Vestal Point Capital, LP725,2460 00For
Connor, Clark & Lunn Investment Management Ltd.598,8700 00For
DE Shaw597,0990 00For
Alyeska Investment Group, L.P.0453,914 00Against
Charles Schwab426,9770 00For
AQR424,6630 00For
ACADIAN ASSET MANAGEMENT LLC396,4992,386 00For
Vanguard359,1280 00For
Northern Trust329,9772,813 00For
Bessemer Trust CO of Delaware, N.A.292,7600 00For
BESSEMER TRUST CO289,2370 00For
BESSEMER TRUST Co OF FLORIDA289,2370 00For
Bessemer Trust Co of California, N.A.289,2370 00For

Institutional-manager reports, all 132 managers: 33,960,399 for, 2,909,445 against, 10,158 abstained, 460 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 58,793,645AGAINST: 36,178

Prior year: 100.0% for (June 26, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 51 asset managers

Description as filed by funds: Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and

Fulcrum Therapeutics, Inc.’s own tally for this item (“Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 58,793,645 for, 36,178 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “d) Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 51 asset managers below reported 9,484,059 for, 55 against, 14,329 abstained.

FOR
FOR: 9,484,059AGAINST: 55ABSTAIN: 14,329
Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,247,8120 00For
BlackRock2,827,0140 00For
Fidelity1,253,3260 00For
Charles Schwab426,9630 00For
State Street343,83455 00For
Dimensional252,6900 00For
American Century156,2420 00For
TIAA129,6180 00For
Simplify Exchange Traded Funds116,8340 00For
Equitable113,2280 00For
QUANTITATIVE MASTER SERIES LLC85,7810 00For
Goldman Sachs75,1940 00For
Lincoln Financial62,5900 00For
Northern Trust43,8960 00For
Russell Investments33,6730 00For
AIG/SunAmerica29,4620 00For
Global X25,9200 00For
Bridge Builder Trust25,4810 00For
ProShares25,4560 00For
MASTER INVESTMENT PORTFOLIO24,0780 00For
Pacific Life22,5500 00For
CLEARWATER INVESTMENT TRUST20,3610 00For
Brighthouse19,2480 00For
John Hancock14,6420 00For
Jackson National14,6310 00For

Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).

Largest Fulcrum Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 66,633,321 shares outstanding at the time of that meeting.

Fund voting reports: top Fulcrum Therapeutics, Inc. shareholders by shares voted on “A non-binding advisory vote to approve the compensation of our named executive officers;”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 4.87%
2BlackRock 4.24%
3Fidelity 1.88%
4Charles Schwab 0.64%
5State Street 0.52%
6Dimensional 0.38%
7American Century 0.23%
8TIAA 0.19%
9Simplify Exchange Traded Funds 0.18%
10Equitable 0.17%
Institutional-manager reports: top Fulcrum Therapeutics, Inc. shareholders by shares voted on “A non-binding advisory vote to approve the compensation of our named executive officers;”, 2025-2026
#Asset manager % of shares outstanding
1MONTANOVA CAPITAL, LLC 9.70%
2RA CAPITAL MANAGEMENT, L.P. 9.09%
3Nantahala Capital Management, LLC 3.65%
4Siren, L.L.C. 3.60%
5BlackRock 3.39%
6Aberdeen 3.32%
7State Street 2.06%
8GEODE CAPITAL MANAGEMENT, LLC 2.05%
9BRAIDWELL LP 1.50%
10Point72 1.50%

Reported Fulcrum Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Fulcrum Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
RA Capital Management, L.P.6,649,973 9.98%Proxy statement (DEF 14A), table as of March 31, 2026
Suvretta Capital Management, LLC6,178,505 9.27%Proxy statement (DEF 14A), table as of March 31, 2026
Nantahala Capital Management, LLC5,677,912 8.52%Proxy statement (DEF 14A), table as of March 31, 2026
BlackRock5,390,593 8.09%Form 13F, quarter ended March 31, 2026
TCG Crossover GP II, LLC5,000,000 7.50%Proxy statement (DEF 14A), table as of March 31, 2026
BANK OF AMERICA CORP /DE/4,468,123 6.71%Schedule 13G, filed August 3, 2026
Montanova Capital, LLC3,680,921 5.52%Schedule 13G, filed August 14, 2026
Vanguard Group3,559,552 5.34%Form 13F, quarter ended March 31, 2026
Alex C. Sapir2,096,219 3.15%Proxy statement (DEF 14A), table as of March 31, 2026
Point722,074,855 3.11%Form 13F, quarter ended March 31, 2026

Percentages above are of 66,633,321 shares outstanding, as reported by Fulcrum Therapeutics, Inc. on its Form 10-Q dated April 20, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Fulcrum Therapeutics, Inc.'s shareholder meeting held June 24, 2026, in the 2025-2026 proxy season, 169 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 951 separate fund positions. On the most widely held item on that ballot — A non-binding advisory vote to approve the compensation of our named executive officers; — Fulcrum Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Fulcrum Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 25, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Fulcrum Therapeutics, Inc.’s 10-Q dated April 20, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Fulcrum Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Fulcrum Therapeutics (FULC) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/fulcrum-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.